Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- dospělí MeSH
- konformní radioterapie metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory hypofaryngu mortalita patologie radioterapie MeSH
- nádory nosohltanu mortalita patologie radioterapie MeSH
- nádory úst mortalita patologie radioterapie MeSH
- následné studie MeSH
- otorinolaryngologické nádory mortalita patologie radioterapie MeSH
- přežití bez známek nemoci MeSH
- radiační poranění etiologie MeSH
- radioterapie s modulovanou intenzitou metody MeSH
- senioři MeSH
- staging nádorů MeSH
- studie proveditelnosti MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
Zobrazit více v PubMed
Strahlenther Onkol. 2010 Sep;186(9):511-6 PubMed
Clin Oncol (R Coll Radiol). 2008 Mar;20(2):113-26 PubMed
Radiother Oncol. 1994 Apr;31(1):14-22 PubMed
Lancet. 2003 Sep 20;362(9388):933-40 PubMed
Br J Radiol. 1994 Aug;67(800):790-4 PubMed
Strahlenther Onkol. 2009 Oct;185(10):682-8 PubMed
Radiother Oncol. 1997 Aug;44(2):123-36 PubMed
Radiother Oncol. 2009 Feb;90(2):166-71 PubMed
Clin Oncol (R Coll Radiol). 2008 Apr;20(3):212-20 PubMed
Strahlenther Onkol. 2010 Sep;186(9):489-95 PubMed
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):62-9 PubMed
Radiother Oncol. 2005 Feb;74(2):93-100 PubMed
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):8-22 PubMed
Curr Opin Oncol. 2004 May;16(3):215-9 PubMed
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):807-19 PubMed
Radiother Oncol. 2003 Nov;69(2):161-8 PubMed
Strahlenther Onkol. 2009 Oct;185(10):675-81 PubMed
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 PubMed
Radiother Oncol. 1996 Aug;40(2):137-45 PubMed
Radiother Oncol. 1992 Dec;25(4):231-41 PubMed
Lancet. 2000 Mar 18;355(9208):949-55 PubMed
N Engl J Med. 2006 Feb 9;354(6):567-78 PubMed
